---
title: æ™®ç‘å·´æ—
description: 
published: true
date: 2026-01-29T16:31:53.247Z
tags: freeodwikiæ˜¯ä¸€ä¸ªå¼€æºé¡¹ç›®ï¼Œæä¾›æœ‰å…³odã€overdoseã€è¯ç‰©æ»¥ç”¨ã€è¯ç‰©è¿‡é‡ã€å¸æ¯’ã€æ¯’å“ã€ç¦æ¯’ç­‰è¯é¢˜çš„çŸ¥è¯†ã€‚
editor: markdown
dateCreated: 2026-01-24T19:39:45.986Z
---

# æ™®ç‘å·´æ—ï¼ˆPregabalinï¼‰

>
> æŸè‡ªåª’ä½“ï¼šå¤„æ–¹è¯å˜â€œç˜¾å“â€ï¼Œä¸”è´­ä¹°å®¡æ ¸ä¸ä¸¥ï¼
>
> æˆ‘ï¼šä½ åˆ«è¿‡æ¥å•Šå•Šå•Šå•Šå•Šï¼
>

[â—€è¿”å›è¯ç‰©](./home.md)

<mark>æ„Ÿè§‰è´¨é‡ä¸é”™ï¼Œä½†æ˜¯é“¾æ¥è¿˜æ˜¯æœ‰ç‚¹é—®é¢˜ï¼Œè°¨æ…ç‚¹å‡»ä¸æ˜é“¾æ¥ï¼</mark>

# æ™®ç‘å·´æ— (Pregabalin)

**âš ï¸ è­¦å‘Šï¼šå½“[åŠ å·´å–·ä¸ç±»](./åŠ å·´å–·ä¸ç±».md)ä¸[é˜¿ç‰‡ç±»è¯ç‰©](./é˜¿ç‰‡ç±»è¯ç‰©.md)ã€[è‹¯äºŒæ°®å“ç±»](./è‹¯äºŒæ°®å“ç±».md)ã€[å·´æ¯”å¦¥ç±»](./å·´æ¯”å¦¥ç±».md)ã€[å™»å©äºŒæ°®å“ç±»](./å™»å©äºŒæ°®å“ç±».md)ã€[é…’ç²¾](./é…’ç²¾.md)æˆ–å…¶ä»–[GABAèƒ½ç‰©è´¨](./GABA.md)ç­‰å…¶ä»–[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)è”ç”¨æ—¶ï¼Œå¯èƒ½å‘ç”Ÿè‡´å‘½çš„[è¿‡é‡](./è¿‡é‡.md)ã€‚[\[1\]](#cite_note-tripsit-1)**

å¼ºçƒˆå»ºè®®ä¸è¦è”ç”¨è¿™äº›ç‰©è´¨ï¼Œç‰¹åˆ«æ˜¯åœ¨[æ™®é€š](./å‰‚é‡åˆ†ç±».md)åˆ°[å¼º](./å‰‚é‡åˆ†ç±».md)å‰‚é‡çš„èŒƒå›´å†…ã€‚

---

| æ™®ç‘å·´æ— (Pregabalin) | |
| --- | --- |
| åŒ–å­¦å‘½å | |
| é€šç”¨åç§° | *Pregabalin, Lyrica, Nervalin* |
| å–ä»£åç§° | *3-Isobutyl GABA* |
| ç³»ç»Ÿå‘½å | *(S)-3-(Aminomethyl)-5-methylhexanoic acid* |
| åˆ†ç±» | |
| ç²¾ç¥æ´»æ€§åˆ†ç±» | *[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)* |
| åŒ–å­¦åˆ†ç±» | *[åŠ å·´å–·ä¸ç±»](./åŠ å·´å–·ä¸ç±».md)* |

**âš ï¸ è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€æ–°é™ˆä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»è¾ƒä½å‰‚é‡å¼€å§‹ã€‚[å‚è§ä¼¤å®³å‡å°‘æªæ–½éƒ¨åˆ†](../æ–‡æ¡£/è´Ÿè´£ä»»çš„è¯ç‰©ä½¿ç”¨.md)ã€‚

### â‡£ [å£æœ](../æ–‡æ¡£/ç»™è¯é€”å¾„.md)

| æ•°æ®é¡¹ | æ•°å€¼ |
| --- | --- |
| **[å‰‚é‡](../æ–‡æ¡£/å‰‚é‡.md)** | |
| [ç”Ÿç‰©åˆ©ç”¨åº¦](../æ–‡æ¡£/å‰‚é‡.md#Bioavailability) | ~90%[\[2\]](#cite_note-Bockbrader2010-2) |
| [é˜ˆå€¼](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 50 mg |
| [è½»åº¦](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 50 - 225 mg |
| [æ™®é€š](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 225 - 600 mg |
| [å¼º](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 600 - 900 mg |
| [æå¼º](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 900 mg + |
| **[èµ·æ•ˆæ—¶é—´](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 9 - 17 å°æ—¶ |
| [èµ·æ•ˆ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 30 - 45 åˆ†é’Ÿ |
| [æ¥æ•ˆ (Come up)](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 1 - 2 å°æ—¶ |
| [é¡¶å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 4 - 6 å°æ—¶ |
| [ä¸‹é™](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 4 - 8 å°æ—¶ |
| [ä½™éŸµ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 4 - 10 å°æ—¶ |

### â‡£ [ç›´è‚ ç»™è¯](../æ–‡æ¡£/ç»™è¯é€”å¾„.md)

| æ•°æ®é¡¹ | æ•°å€¼ |
| --- | --- |
| **[å‰‚é‡](../æ–‡æ¡£/å‰‚é‡.md)** | |
| [ç”Ÿç‰©åˆ©ç”¨åº¦](../æ–‡æ¡£/å‰‚é‡.md#Bioavailability) | ~99% |
| [é˜ˆå€¼](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | < 40 mg |
| [è½»åº¦](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 40 - 200 mg |
| [æ™®é€š](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 200 - 450 mg |
| [å¼º](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 450 - 600 mg |
| [æå¼º](../æ–‡æ¡£/å‰‚é‡åˆ†ç±».md) | 600 mg+ |
| **[èµ·æ•ˆæ—¶é—´](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 5 - 8 å°æ—¶ |
| [èµ·æ•ˆ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 15 - 30 åˆ†é’Ÿ |
| [æ¥æ•ˆ (Come up)](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 30 - 120 åˆ†é’Ÿ |
| [é¡¶å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 2 - 3 å°æ—¶ |
| [ä¸‹é™](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 3 - 5 å°æ—¶ |
| [ä½™éŸµ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 6 - 12 å°æ—¶ |

**[å…è´£å£°æ˜](../æ–‡æ¡£/å…è´£å£°æ˜.md)ï¼š** PsychonautWiki çš„[å‰‚é‡](../æ–‡æ¡£/å‰‚é‡.md)ä¿¡æ¯ç”±ç”¨æˆ·å’Œ[ç›¸å…³èµ„æº](../æ–‡æ¡£/ç½‘ç»œ.md)æ”¶é›†è€Œæ¥ï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯å»ºè®®ï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚

### [ç›¸äº’ä½œç”¨](#Dangerous_interactions)

*   Oxycodone (ç¾Ÿè€ƒé…®): ğŸ’” å±é™©
*   SSRI (é€‰æ‹©æ€§5-ç¾Ÿè‰²èƒºå†æ‘„å–æŠ‘åˆ¶å‰‚): âš ï¸ æ…ç”¨
*   MDMA (æ‘‡å¤´ä¸¸): âš ï¸ æ…ç”¨

---

**æ™®ç‘å·´æ—**ï¼ˆ**Pregabalin**ï¼Œä¹Ÿç§°ä¸º **3-å¼‚ä¸åŸº GABA**ï¼Œå•†å“åä¸º **Lyrica/ä¹ç‘å¡**ï¼‰æ˜¯ä¸€ç§[åŠ å·´å–·ä¸ç±»](./åŠ å·´å–·ä¸ç±».md)çš„[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ç‰©è´¨ã€‚æ™®ç‘å·´æ—æ˜¯ä¸€ç§å¸¸è§çš„å¤„æ–¹è¯ï¼Œé€šå¸¸ç”¨äºæ²»ç–—ç¥ç»æ€§ç–¼ç—›ã€[ç„¦è™‘](../è¯æ•ˆ/ç„¦è™‘æŠ‘åˆ¶.md)ã€[ä¸å®è…¿ç»¼åˆå¾](./ä¸å®è…¿ç»¼åˆå¾.md)ï¼Œå¹¶ä½œä¸ºæ²»ç–—[ç™«ç—«](./ç™«ç—«.md)çš„è¾…åŠ©è¯ç‰©ã€‚[\[3\]](#cite_note-3)[\[4\]](#cite_note-4)

æ™®ç‘å·´æ—å…·æœ‰ä¸[åŠ å·´å–·ä¸](./åŠ å·´å–·ä¸.md)ç›¸å½“çš„è¯ç†å­¦ç‰¹å¾ï¼Œå› ä¸ºå®ƒä»¬éƒ½å…·æœ‰ç›¸ä¼¼çš„ä½œç”¨æœºåˆ¶å¹¶äº§ç”Ÿç›¸ä¼¼çš„ä¸»è§‚æ•ˆåº”ã€‚æ™®ç‘å·´æ—ç›¸å¯¹äºåŠ å·´å–·ä¸çš„ä¼˜åŠ¿åŒ…æ‹¬æ›´é«˜çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œæ•ˆåŠ›ï¼Œ[\[5\]](#cite_note-5) æ­¤å¤–ï¼Œæ™®ç‘å·´æ—æ‹¥æœ‰æ¯”åŠ å·´å–·ä¸æ›´å¹¿æ³›çš„è·æ‰¹åŒ»ç–—ç”¨é€”ï¼Œä¾‹å¦‚åœ¨æ²»ç–—ç„¦è™‘æ–¹é¢ï¼ŒåŠ å·´å–·ä¸å¹¶ä¸æˆåŠŸï¼ˆé™¤äº†ä¸€äº›è¾ƒä¸¥é‡çš„ç—…ä¾‹ï¼‰ã€‚[\[6\]](#cite_note-6) [\[7\]](#cite_note-7)

## ç›®å½•

*   [1 åŒ–å­¦](#Chemistry)
*   [2 è¯ç†å­¦](#Pharmacology)
    *   [2.1 è¯æ•ˆå­¦](#Pharmacodynamics)
    *   [2.2 è¯ä»£åŠ¨åŠ›å­¦](#Pharmacokinetics)
*   [3 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    *   [3.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    *   [3.2 **è§†è§‰æ•ˆåº”**](#Visual_effects)
        *   [3.2.1 å¹»è§‰çŠ¶æ€](#Hallucinatory_states)
    *   [3.3 **è§£ç¦»æ•ˆåº”**](#Disconnective_effects)
    *   [3.4 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    *   [3.5 **å¬è§‰æ•ˆåº”**](#Auditory_effects)
    *   [3.6 **åé—æ•ˆåº”**](#After_effects)
    *   [3.7 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
*   [4 åŒ»ç–—ç”¨é€”](#Medical_uses)
    *   [4.1 ç™«ç—«é¢„é˜²](#Seizure_Prevention)
    *   [4.2 ç¥ç»æ€§ç–¼ç—›](#Neuropathic_pain)
    *   [4.3 ç„¦è™‘ç—‡](#Anxiety_disorders)
    *   [4.4 ç‰©è´¨ä½¿ç”¨éšœç¢](#Substance_disorders)
        *   [4.4.1 é˜¿ç‰‡ç±»è¯ç‰©](#Opioids)
        *   [4.4.2 çƒŸè‰](#Tobacco)
        *   [4.4.3 é…’ç²¾](#Alcohol)
        *   [4.4.4 è‹¯äºŒæ°®å“ç±»](#Benzodiazepines)
*   [5 æ¯’æ€§å’Œæ½œåœ¨å±å®³](#Toxicity_and_harm_potential)
    *   [5.1 ç™«ç—«é£é™©](#Seizure_Risk)
    *   [5.2 è‡´æ­»å‰‚é‡](#Lethal_dosage)
    *   [5.3 è€å—æ€§å’Œæˆç˜¾æ½œåŠ›](#Tolerance_and_addiction_potential)
    *   [5.4 ç›¸äº’ä½œç”¨](#Interactions)
*   [6 æ³•å¾‹åœ°ä½](#Legal_status)
*   [7 å¦è§](#See_also)
*   [8 å¤–éƒ¨é“¾æ¥](#External_links)
*   [9 æ–‡çŒ®](#Literature)
*   [10 å‚è€ƒæ–‡çŒ®](#References)

## åŒ–å­¦

æ™®ç‘å·´æ—æ˜¯[GABA](./GABA.md)ï¼ˆÎ³-æ°¨åŸºä¸é…¸ï¼‰çš„ç»“æ„ç±»ä¼¼ç‰©ï¼Œåœ¨æ°¨åŸºä¸é…¸é“¾çš„Î²ç¢³ä¸Šå–ä»£äº†ä¸€ä¸ªå¼‚ä¸åŸºã€‚æ™®ç‘å·´æ—åœ¨ç»“æ„ä¸Šä¸å…¶ä»–[åŠ å·´å–·ä¸ç±»è¯ç‰©](./åŠ å·´å–·ä¸ç±».md)ç›¸ä¼¼ï¼Œå¦‚[åŠ å·´å–·ä¸](./åŠ å·´å–·ä¸.md)å’Œ[è²å°¼å¸ƒç‰¹](./è²å°¼å¸ƒç‰¹.md)ã€‚æ™®ç‘å·´æ—å«æœ‰ä¸€ä¸ªè¢«ç§°ä¸ºå·±é…¸çš„ç¾§åŒ–å·±çƒ·é“¾ã€‚è¯¥ç¢³é“¾åœ¨ R3 ä½ç½®ä»¥ (S) æ„å‹é€šè¿‡ç”²åŸºæ¡¥å–ä»£äº†ä¸€ä¸ªèƒºåŸºï¼Œå¹¶åœ¨ R5 ä½ç½®å–ä»£äº†ä¸€ä¸ªç”²åŸºã€‚

## è¯ç†å­¦

æ™®ç‘å·´æ—æ—¢ä¸æ˜¯ GABAA å—ä½“æ¿€åŠ¨å‰‚ï¼Œä¹Ÿä¸æ˜¯ GABAB å—ä½“æ¿€åŠ¨å‰‚ã€‚

### è¯æ•ˆå­¦

æ™®ç‘å·´æ—çš„è¯ç†ä½œç”¨æ˜¯é€šè¿‡ä¸ç”µå‹é—¨æ§é’™é€šé“çš„ Î±2Î´-1 ä½ç‚¹ç»“åˆä»‹å¯¼çš„ã€‚[\[8\]](#cite_note-8)[\[9\]](#cite_note-thromb-9) è¯¥ä½ç‚¹ä¹Ÿè¢«ç§°ä¸ºåŠ å·´å–·ä¸å—ä½“ï¼Œå› ä¸ºå®ƒæ˜¯ç›¸å…³ç‰©è´¨[åŠ å·´å–·ä¸](./åŠ å·´å–·ä¸.md)ï¼ˆä¹Ÿæ˜¯ç”±è¾‰ç‘å…¬å¸å¼€å‘ï¼‰çš„é¶ç‚¹ã€‚æ™®ç‘å·´æ—ç›¸å¯¹äºåŠ å·´å–·ä¸çš„ä¼˜åŠ¿åŒ…æ‹¬æ›´é«˜çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œæ•ˆåŠ›ã€‚

è™½ç„¶æ™®ç‘å·´æ—æ˜¯[GABA](./GABA.md)çš„åŒ–å­¦è¡ç”Ÿç‰©ï¼Œä½†å®ƒå¯¹ä»»ä½• GABA å—ä½“ï¼ˆåŒ…æ‹¬ GABAAã€GABAB å’Œ[è‹¯äºŒæ°®å“](./è‹¯äºŒæ°®å“ç±».md)ä½ç‚¹ï¼‰å‡ä¸æ˜¾ç¤ºæ´»æ€§ã€‚å°½ç®¡æ™®ç‘å·´æ—å…·æœ‰ GABA éª¨æ¶ï¼Œä½†å®ƒä¼¼ä¹ä¸ä¼šæ”¹å˜å¤§è„‘ä¸­çš„ GABA æ°´å¹³ï¼Œå› æ­¤æ¨æµ‹å…¶è¯ç†æ´»æ€§ä¸ GABA æ— å…³ã€‚[\[10\]](#cite_note-10) ç›¸åï¼Œå®ƒä¸ç”µå‹é—¨æ§é’™é€šé“çš„ Î±2Î´-1 ä½ç‚¹çš„ç»“åˆä¼¼ä¹æ˜¯å…¶ä¸»è§‚æ•ˆåº”çš„æ¥æºã€‚é€šè¿‡ç»“åˆè¯¥ä½ç‚¹ï¼Œæ™®ç‘å·´æ—å‡å°‘äº†å‡ ç§å…´å¥‹æ€§ç¥ç»é€’è´¨çš„é‡Šæ”¾ï¼ŒåŒ…æ‹¬[è°·æ°¨é…¸](./è°·æ°¨é…¸.md)ã€[Pç‰©è´¨](./Pç‰©è´¨.md)ã€[ä¹™é…°èƒ†ç¢±](./ä¹™é…°èƒ†ç¢±.md)å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](./å»ç”²è‚¾ä¸Šè…ºç´ .md)ã€‚[\[11\]](#cite_note-11)

è°·æ°¨é…¸å’Œä¹™é…°èƒ†ç¢±é‡Šæ”¾çš„å‡å°‘å¯èƒ½æ˜¯é«˜å‰‚é‡ä¸‹äº§ç”Ÿè§£ç¦»/è°µå¦„æ ·æ•ˆåº”çš„åŸå› ã€‚\[*[æ¥æºè¯·æ±‚](../æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]

ä¸€é¡¹ç ”ç©¶è¿˜è¡¨æ˜ï¼Œæ™®ç‘å·´æ—èƒ½ä¿ƒè¿›æ·±åº¦ç¡çœ ï¼Œä»è€Œæé«˜ç¡çœ è´¨é‡ã€‚è¿™ä¸€ç‚¹å¯èƒ½å¾ˆé‡è¦ï¼Œå› ä¸ºæ…¢æ³¢ç¡çœ çš„å‡å°‘ä¸ç„¦è™‘å’Œçº¤ç»´è‚Œç—›æœ‰å…³ã€‚[\[12\]](#cite_note-12) æ­¤å¤–ï¼Œè¿˜å‘ç°äº†åŠ å·´å–·ä¸ä½ç‚¹å¯¹å…´å¥‹æ€§çªè§¦ç¥ç»å‘ç”Ÿçš„ç‹¬ç«‹ä½œç”¨ã€‚å†…æºæ€§ç¥ç»åŒ–å­¦ç‰©è´¨è¡€å°æ¿ååº”è›‹ç™½ï¼ˆthrombospondinï¼‰ä¹Ÿç»“åˆåœ¨è¯¥ä½ç‚¹ï¼Œå¯¹æ–°å…´å¥‹æ€§çªè§¦çš„ç”Ÿæˆå¾ˆé‡è¦ã€‚åŠ å·´å–·ä¸å’Œæ™®ç‘å·´æ—å¯¹è¯¥ä½ç‚¹å…·æœ‰é«˜äº²å’ŒåŠ›ï¼Œåœ¨åŠ¨ç‰©æ¨¡å‹ä¸­å¯é˜»æ–­è¯¥ä½œç”¨å¹¶å¯¼è‡´å…´å¥‹æ€§çªè§¦æ°´å¹³é™ä½ã€‚[\[9\]](#cite_note-thromb-9)

ç”±äºæ™®ç‘å·´æ—æ²»ç–—ä¸å¤§è„‘è¿‡åº¦å…´å¥‹ç›¸å…³çš„ç–¾ç—…å’Œ[ç¥ç»é€’è´¨](./ç¥ç»é€’è´¨.md)ï¼ˆç„¦è™‘ã€ç™«ç—«ã€ç¥ç»æ€§ç–¼ç—›ï¼‰ï¼Œå…¶è°ƒèŠ‚ä½œç”¨å¯¼è‡´äº†æ™®ç‘å·´æ—å¯¹ç¥ç»ç³»ç»Ÿçš„[é•‡é™](../è¯æ•ˆ/é•‡é™.md)ï¼ˆæˆ–[å¹³é™](../è¯æ•ˆ/ç„¦è™‘æŠ‘åˆ¶.md)ï¼‰æ•ˆåº”ã€‚\[*[æ¥æºè¯·æ±‚](../æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]

### è¯ä»£åŠ¨åŠ›å­¦

æ™®ç‘å·´æ—ç©ºè…¹æœç”¨æ—¶å¸æ”¶è¿…é€Ÿï¼Œè¡€æµ†æµ“åº¦å³°å€¼å‡ºç°åœ¨ 1 åˆ° 1.5 å°æ—¶å†…ã€‚æ™®ç‘å·´æ—çš„å£æœç”Ÿç‰©åˆ©ç”¨åº¦ä¼°è®¡å¤§äºæˆ–ç­‰äº 90%ã€‚ä¸é£Ÿç‰©åŒæœæ—¶ï¼Œæ™®ç‘å·´æ—çš„å¸æ”¶ç‡é™ä½ï¼Œè¾¾åˆ°è¡€æµ†æµ“åº¦å³°å€¼çš„æ—¶é—´å»¶è¿Ÿçº¦ 3 å°æ—¶ï¼Œä¸”å³°å€¼æ°´å¹³æœ¬èº«é™ä½çº¦ 25% åˆ° 30%ã€‚[\[13\]](#cite_note-13) ç„¶è€Œï¼Œä¸é£Ÿç‰©åŒæœå¯¹å¸æ”¶ç¨‹åº¦æ²¡æœ‰ä¸´åºŠæ˜¾ç€å½±å“ã€‚[\[14\]](#cite_note-14)

æ™®ç‘å·´æ—åœ¨äººä½“å†…çš„ä»£è°¢å¯å¿½ç•¥ä¸è®¡ã€‚åœ¨ä½¿ç”¨æ ¸åŒ»å­¦æŠ€æœ¯çš„å®éªŒä¸­æ˜¾ç¤ºï¼Œå°¿æ¶²ä¸­å›æ”¶çš„æ”¾å°„æ€§çº¦ 98% ä¸ºæœªæ”¹å˜çš„æ™®ç‘å·´æ—ã€‚ä¸»è¦ä»£è°¢äº§ç‰©æ˜¯ N-ç”²åŸºæ™®ç‘å·´æ—ã€‚

æ™®ç‘å·´æ—ä¸»è¦é€šè¿‡è‚¾è„ä»¥åŸå½¢ç‰©è´¨çš„å½¢å¼ä»ä½“å¾ªç¯ä¸­æ¸…é™¤ã€‚[\[15\]](#cite_note-15) æ¸…é™¤åŠè¡°æœŸä¸º 6.3 å°æ—¶ã€‚[\[16\]](#cite_note-16)

## ä¸»è§‚æ•ˆåº”

æ¯ä¸ªäººå¯¹æ™®ç‘å·´æ—çš„ååº”éƒ½å¯èƒ½æœ‰å¾ˆå¤§ä¸åŒï¼Œå› æ­¤å¿…é¡»ä»ä½å‰‚é‡å¼€å§‹ï¼Œä»¥ç¡®ä¿ä¸ä¼šäº§ç”Ÿä»»ä½•ä¸¥é‡çš„å‰¯ä½œç”¨ï¼Œå¦‚å‘¨å›´æ°´è‚¿æˆ–è‚Œè‚‰ç–¼ç—›ã€‚

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª[**ä¸»è§‚æ•ˆåº”ç´¢å¼•**](../è¯æ•ˆ/ä¸»è§‚æ•ˆåº”ç´¢å¼•.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](../æ–‡æ¡£/PsychonautWiki.md) [è´¡çŒ®è€…](../æ–‡æ¡£/è´¡çŒ®è€….md)çš„ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…è¿™äº›å†…å®¹ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”å¹¶ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚* åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”**

*   **[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md)** & **[é•‡é™](../è¯æ•ˆ/é•‡é™.md)** - æ™®ç‘å·´æ—äº§ç”Ÿè½»å¾®çš„é•‡é™ä½œç”¨ï¼Œå¹¶é€‚åº¦æ”¹å–„å…¥ç¡æ½œä¼æœŸã€‚å‡ é¡¹ç ”ç©¶è¡¨æ˜ï¼Œæ™®ç‘å·´æ—æ”¹å–„äº†å› å„ç§é€‚åº”ç—‡æœç”¨è¯¥è¯çš„äººçš„ç¡çœ è´¨é‡ã€‚ç›®å‰å°šä¸æ¸…æ¥šè¿™ç§æ•ˆæœæ˜¯å¦ä¹Ÿä¼šå‡ºç°åœ¨å¨±ä¹æ€§ç”¨è¯è€…èº«ä¸Šã€‚[\[17\]](#cite_note-17)[\[18\]](#cite_note-18) ç„¶è€Œï¼Œåœ¨ç™½å¤©æœç”¨æ—¶ï¼Œå®ƒå¹¶ä¸æ˜¯ä¸€ç§è¿‡åº¦é•‡é™çš„ç‰©è´¨ã€‚
*   **[é£Ÿæ¬²å¢å¼º](../è¯æ•ˆ/é£Ÿæ¬²å¢å¼º.md)** - è¿™ç§æ•ˆåº”å¹¶ä¸æ˜¯ç‰¹åˆ«çªå‡ºï¼Œä½†æ®æŠ¥é“åœ¨æŸäº›äººèº«ä¸Šä¼šå‘ç”Ÿã€‚ä¸[å¤§éº»](./å››æ°¢å¤§éº»é…šï¼ˆTHCï¼‰.md)è”ç”¨æ—¶å¯èƒ½ä¼šäº§ç”ŸååŒæ•ˆåº”ã€‚
*   **[é•‡ç—›](../è¯æ•ˆ/é•‡ç—›.md)** - æ™®ç‘å·´æ—å¯¹æŸäº›ç±»å‹çš„æ…¢æ€§ç–¼ç—›ï¼ˆç‰¹åˆ«æ˜¯ç¥ç»æ€§ç–¼ç—›ï¼‰æœ‰æ•ˆï¼Œä½†å¯¹æ€¥æ€§ç–¼ç—›æ— æ•ˆã€‚[\[19\]](#cite_note-19)
*   **[è‡ªå‘èº¯ä½“æ„Ÿè§‰](../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)** - æ™®ç‘å·´æ—çš„æ€»ä½“â€œèº¯ä½“å¿«æ„Ÿâ€å¯ä»¥æè¿°ä¸ºä¸€ç§ç‰¹å®šçš„åˆºç—›æ„Ÿï¼Œä¸»è¦é›†ä¸­åœ¨æ‰‹ã€è„šå’Œå¤´éƒ¨ã€‚
*   **[èº¯ä½“æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)** - è¿™ä¸€æˆåˆ†è™½ç„¶åœ¨ä½“éªŒä¸­å¾ˆçªå‡ºï¼Œä½†é€šå¸¸ä¸å¦‚å®ƒèƒ½è¯±å‘çš„è®¤çŸ¥æ¬£å¿«æ„Ÿå¼ºçƒˆã€‚è¿™ç§æ„Ÿè§‰æœ¬èº«å¯ä»¥æè¿°ä¸ºèº«ä½“èˆ’é€‚ã€æ¸©æš–å’Œå¹¸ç¦çš„æ„Ÿè§‰ã€‚
*   **[è§¦è§‰å¢å¼º](../è¯æ•ˆ/è§¦è§‰æ•ˆåº”%20-%20home.md)** - è™½ç„¶ä½¿ç”¨è€…çš„èº«ä½“å¯èƒ½æ„Ÿåˆ°éº»æœ¨ï¼Œä½†è§¦è§‰åŒæ—¶ä¹Ÿå¯èƒ½å˜å¾—æ•é”ã€‚
*   **[è‚Œè‚‰é¢¤åŠ¨](../è¯æ•ˆ/è‚Œè‚‰é¢¤åŠ¨.md)** - æœ‰ç‚¹çŸ›ç›¾çš„æ˜¯ï¼Œè™½ç„¶æ™®ç‘å·´æ—è¢«ç”¨ä½œç™«ç—«çš„è¾…åŠ©æ²»ç–—ï¼Œä½†æ™®ç‘å·´æ—ï¼ˆç‰¹åˆ«æ˜¯åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼‰å¯èƒ½ä¼šäº§ç”Ÿè‚Œè‚‰ç—‰æŒ›ã€‚\[*[æ¥æºè¯·æ±‚](../æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\] æ®è½¶äº‹æŠ¥é“ï¼Œè¿‡é‡æœç”¨æ›¾å¼•å‘ç™«ç—«å‘ä½œã€‚\[*[æ¥æºè¯·æ±‚](../æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
*   **[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)** - è™½ç„¶æ™®ç‘å·´æ—å¯èƒ½å¼•èµ·å‘¼å¸æŠ‘åˆ¶ï¼Œä½†è¿™ç§æ•ˆåº”ä¸å¦‚[é˜¿ç‰‡ç±»è¯ç‰©](./é˜¿ç‰‡ç±»è¯ç‰©.md)å’Œ[è‹¯äºŒæ°®å“ç±»è¯ç‰©](./è‹¯äºŒæ°®å“ç±».md)å¼ºçƒˆã€‚[\[20\]](#cite_note-20)
*   **[è‚Œè‚‰æ¾å¼›](../è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)** - è™½ç„¶æ™®ç‘å·´æ—çš„è‚Œè‚‰æ¾å¼›ä½œç”¨ä¸å¦‚[åœ°è¥¿æ³®](./åœ°è¥¿æ³®.md)æˆ–å…¶ä»–[è‹¯äºŒæ°®å“ç±»è¯ç‰©](./è‹¯äºŒæ°®å“ç±».md)å¼ºå¤§ï¼Œä½†ä»ç„¶å¾ˆæ˜æ˜¾ã€‚
*   **[å¤´æ™•](../è¯æ•ˆ/å¤´æ™•.md)** - è¿™ç§æ•ˆåº”åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ç›¸å½“æ™®éã€‚
*   **[èº¯ä½“è½»ç›ˆæ„Ÿ](../è¯æ•ˆ/èº¯ä½“è½»ç›ˆæ„Ÿ.md)** - åœ¨æé«˜å‰‚é‡ä¸‹ï¼Œä¸€äº›ç”¨æˆ·æŠ¥å‘Šæ„Ÿè§‰å˜è½»äº†ã€‚
*   **[æ€§æ¬²å¢å¼º](../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)** *æˆ–* **[æ€§æ¬²å‡é€€](../è¯æ•ˆ/æ€§æ¬²å‡é€€.md)**
*   **[æ€§é«˜æ½®æŠ‘åˆ¶](../è¯æ•ˆ/æ€§é«˜æ½®æŠ‘åˆ¶.md)** - å³ä½¿æ€§æ¬²å¢åŠ ï¼Œæœ‰äº›äººä¹Ÿå¯èƒ½ä¼šç»å†å»¶è¿Ÿä½†æ›´å¼ºçƒˆçš„æ€§é«˜æ½®ã€‚
*   **[æ’å°¿å›°éš¾](../è¯æ•ˆ/æ’å°¿å›°éš¾.md)** - ç”¨æˆ·å¸¸æŠ¥å‘Šæ­¤æ•ˆåº”ã€‚
*   **[å°¿é¢‘](../è¯æ•ˆ/å°¿é¢‘.md)**
*   **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](../è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)** - åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œæ­¤æ•ˆåº”ç±»ä¼¼äº[è‹¯äºŒæ°®å“ç±»è¯ç‰©](./è‹¯äºŒæ°®å“ç±».md)å’Œ[é…’ç²¾](./é…’ç²¾.md)ã€‚ç”¨æˆ·æŠ¥å‘Šä¼šæ­¥å±¥è¹’è·šå¹¶æ’åˆ°å¢™å£ã€‚
*   **[è§¦è§‰æŠ‘åˆ¶](../è¯æ•ˆ/è§¦è§‰æ•ˆåº”%20-%20home.md)** - è¿™ç§æ•ˆåº”å¯èƒ½å¯¼è‡´å…¨èº«æ„Ÿåˆ°éº»æœ¨ï¼Œå°¤å…¶æ˜¯é¢éƒ¨ã€‚ä¸æ­¤åŒæ—¶ï¼Œä½¿ç”¨è€…çš„è§¦è§‰å¯èƒ½ä¼šå¢å¼ºã€‚
*   **[ç™«ç—«å‘ä½œæŠ‘åˆ¶](../è¯æ•ˆ/ç™«ç—«å‘ä½œæŠ‘åˆ¶.md)** - æ™®ç‘å·´æ—å¯æœ‰æ•ˆå‡å°‘æŸäº›ç±»å‹çš„ç™«ç—«å‘ä½œï¼Œå¦‚å±€ç¶æ€§ç™«ç—«å‘ä½œå’Œéƒ¨åˆ†æ€§ç™«ç—«å‘ä½œã€‚[\[21\]](#cite_note-21)[\[22\]](#cite_note-22)
*   **[ç³å­”æ‰©å¤§](../è¯æ•ˆ/ç³å­”æ‰©å¤§.md)**

### **è§†è§‰æ•ˆåº”**

*   **[é¢œè‰²å¢å¼º](../è¯æ•ˆ/é¢œè‰²å¢å¼º.md)**
*   **[è§†è§‰é”åº¦æŠ‘åˆ¶](../è¯æ•ˆ/è§†è§‰é”åº¦æŠ‘åˆ¶.md)** - åœ¨é«˜å‰‚é‡ä¸‹ï¼Œæ™®ç‘å·´æ—ä¼šå¯¼è‡´è§†åŠ›è½»å¾®æ¨¡ç³Šã€‚
*   **[æ®‹å½±](../è¯æ•ˆ/æ®‹å½±.md)** - è¿™ç§æ•ˆåº”åœ¨é«˜å‰‚é‡ä¸‹å¯è§ï¼Œé€šå¸¸ç›¸å½“è½»å¾®ã€‚é€šå¸¸ä¸ä¼šè¶…è¿‡ 2 çº§ã€‚
*   **[æ·±åº¦æ„ŸçŸ¥æ‰­æ›²](../è¯æ•ˆ/æ·±åº¦æ„ŸçŸ¥æ‰­æ›².md)** - è¿™ç§æ•ˆåº”ç›¸å½“è½»å¾®ï¼Œä»…åœ¨æé«˜å‰‚é‡ä¸‹å‡ºç°ã€‚
*   **[ç‰©ä½“å˜å½¢](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)** - è™½ç„¶è¿™ç§æ•ˆåº”å¾ˆå°‘è§ï¼Œä½†å®ƒä»ç„¶å¯èƒ½è‡ªå‘å‘ç”Ÿï¼Œé€šå¸¸æ˜¯åœ¨é‡å‰‚é‡ä¸‹ã€‚
*   **[æ¼‚ç§»](../è¯æ•ˆ/æ¼‚ç§».md)**
*   **[è§†è§‰æ®‹ç•™](../è¯æ•ˆ/æ®‹å½±.md)** å’Œ **[å¸§ç‡æŠ‘åˆ¶](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)** - åœ¨é«˜/æé«˜å‰‚é‡ä¸‹ã€‚è¿™ä¸¤ç§æ•ˆåº”åŠ åœ¨ä¸€èµ·ä¼šä½¿ä½ çš„è§†è§‰æ„Ÿè§‰æ›´â€œæ…¢â€ã€‚
*   **[å¤è§†](../è¯æ•ˆ/å¤è§†.md)** - è¿™ç§æ•ˆåº”ç›¸å½“è½»å¾®ï¼Œåœ¨é«˜å‰‚é‡ä¸‹ä¸ä¸€è‡´åœ°å‡ºç°ã€‚

#### å¹»è§‰çŠ¶æ€

è™½ç„¶æ™®ç‘å·´æ—é€šå¸¸ä¸è¢«è®¤ä¸ºæ˜¯è‡´å¹»è¯ç‰©ï¼Œä½†å®ƒåœ¨è¾ƒé«˜å‰‚é‡ä¸‹ä»ä¼šå¯¼è‡´è§£ç¦»ç”šè‡³ç²¾ç¥ç—…æ ·çš„æ•ˆåº”ã€‚ç¡çœ å‰¥å¤ºå’Œé—ä¼ å› ç´ å¯èƒ½åœ¨æ™®ç‘å·´æ—çš„å¹»è§‰çŠ¶æ€ä¸­èµ·ä½œç”¨ã€‚æ™®ç‘å·´æ—çš„å¹»è§‰çŠ¶æ€åŒ…æ‹¬ï¼ˆä½†ä¸é™äºï¼‰ï¼š

*   **[å†…å¹»è§‰](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)** - åœ¨é«˜å‰‚é‡ä¸‹ï¼Œä¸€ä¸ªäººå¯èƒ½ä¼šç»å†æ¢¦å¢ƒèˆ¬çš„çŠ¶æ€å’Œ[å…¥ç¡å¹»è§‰](./å…¥ç¡å¹»è§‰.md)ã€‚
*   **[å¤–å¹»è§‰](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)** - è¿™ç§æ•ˆåº”å¾ˆå°‘è§ï¼Œä»…åœ¨é‡å‰‚é‡å’Œ/æˆ–ä½¿ç”¨è€…ç¡çœ ä¸è¶³æ—¶å‘ç”Ÿã€‚è¿™ç§æ•ˆåº”æœ¬è´¨ä¸Šå¯èƒ½æ˜¯è°µå¦„/ç²¾ç¥ç—…çš„ã€‚å®ƒå¯ä»¥åŒ…æ‹¬ï¼š[ç‰©ä½“æ¿€æ´»](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)ã€[å½±å­äºº](./å½±å­äºº.md)å’Œ[å˜å½¢](../è¯æ•ˆ/è§†è§‰æ•ˆåº”%20-%20home.md)ã€‚å®ƒç”šè‡³å¯èƒ½åŒ…æ‹¬è¿œå¤„ä¸å­˜åœ¨çš„äººå’ŒåŠ¨ç‰©ï¼Œä½†ä¸€æ—¦ä½¿ç”¨è€…èµ°è¿‘ï¼Œä»–ä»¬å¯èƒ½ä¼šæ¶ˆå¤±ã€‚

### **[è§£ç¦»æ•ˆåº”](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)**

*   **[è§†è§‰åˆ†ç¦»](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)** - è¿™ç§æ•ˆåº”é€šå¸¸ç›¸å½“è½»å¾®ï¼Œåœ¨é«˜å‰‚é‡ä¸‹ä¸ä¸€è‡´åœ°å‡ºç°ã€‚å®ƒå¯¼è‡´æ„Ÿè§‰è§†è§‰è·ç¦»é¥è¿œæˆ–æ¨¡ç³Šï¼Œä»¿ä½›æ˜¯é€šè¿‡å±å¹•æˆ–çª—æˆ·è§‚çœ‹ã€‚ç„¶è€Œï¼Œæ™®ç‘å·´æ—å¾ˆå°‘è¢«æŠ¥é“å¼•èµ·[å­”æ´ã€ç©ºé—´å’Œç©ºè™š](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)æˆ–[å¹»è§‰ç»“æ„](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)ã€‚

### **è®¤çŸ¥æ•ˆåº”**

æ™®ç‘å·´æ—çš„è®¤çŸ¥æ•ˆåº”å¯ä»¥åˆ†ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œè¿™äº›éƒ¨åˆ†éšç€å‰‚é‡çš„å¢åŠ è€Œé€æ¸å¢å¼ºã€‚æ™®ç‘å·´æ—çš„ç²¾ç¥çŠ¶æ€å¯æ¯”ä½œæ›´æ¸…é†’çš„[é…’ç²¾](./é…’ç²¾.md)æˆ–[è‹¯äºŒæ°®å“ç±»](./è‹¯äºŒæ°®å“ç±».md)ä¸­æ¯’ï¼Œå°½ç®¡åœ¨é«˜å‰‚é‡ä¸‹å®ƒå¯èƒ½ä¼šå‘ç”Ÿæ›´[è§£ç¦»](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)çš„è½¬å˜ã€‚

è¿™äº›è®¤çŸ¥æ•ˆåº”ä¸­æœ€çªå‡ºçš„é€šå¸¸åŒ…æ‹¬ï¼š

*   **[åˆ†ææŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[å…±æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - æ™®ç‘å·´æ—å‘ˆç°å‡ºç‹¬ç‰¹çš„[ç¥å…¥æ„Ÿ/ç§»æƒ…åŸ](./ç§»æƒ…åŸ.md)æ•ˆåº”ã€‚ä¸[è‹¯äºŒæ°®å“ç±»è¯ç‰©](./è‹¯äºŒæ°®å“ç±».md)ï¼ˆä»…é€šè¿‡[å»æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)å¢åŠ ç¤¾äº¤èƒ½åŠ›ï¼‰ç›¸åï¼Œåœ¨é«˜å‰‚é‡ä¸‹ï¼Œæ™®ç‘å·´æ—ç›´æ¥å¢åŠ äº†ä¸ä»–äººäº¤æµçš„å†²åŠ¨ï¼Œä¼´éšç€åŒç†å¿ƒã€çˆ±ã€äº²å¯†å’Œè”ç³»çš„æ„Ÿè§‰ã€‚è¿™äº›æ•ˆåº”è™½ç„¶æ¯”[MDMA](./MDMA.md)å¼±ï¼Œä½†ä»ç„¶å¾ˆçªå‡ºã€‚
*   **[è‡ªæˆ‘è†¨èƒ€](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æ–°å¥‡æ„Ÿå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æ˜“å—æš—ç¤ºæ€§å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[å¥å¿˜](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - ä¸[è‹¯äºŒæ°®å“ç±»è¯ç‰©](./è‹¯äºŒæ°®å“ç±».md)ç›¸æ¯”ï¼Œå¦‚æœä¸ä¸å…¶ä»–æŠ‘åˆ¶å‰‚è”ç”¨ï¼Œæ™®ç‘å·´æ—ä»…å¼•èµ·è½»å¾®çš„å¥å¿˜ã€‚é•¿æœŸä½¿ç”¨æˆ–é«˜å‰‚é‡ä¸‹ï¼Œåº”é¢„æ–™åˆ°æ›´å¤šçš„â€œè¯åˆ°å˜´è¾¹è¯´ä¸å‡ºâ€çš„æ—¶åˆ»å’ŒçŸ­æœŸè®°å¿†å—æŸï¼ˆä¾‹å¦‚ï¼Œèµ°è¿›æˆ¿é—´å¿˜è®°è¦åœ¨é‚£é‡Œåšä»€ä¹ˆï¼‰ã€‚é™¤éä¸å…¶ä»–ç‰©è´¨è”ç”¨ï¼Œå¦åˆ™ä¼¼ä¹ä¸ä¼šå‘ç”Ÿå®Œå…¨æ–­ç‰‡ã€‚
*   **[ç„¦è™‘æŠ‘åˆ¶](../è¯æ•ˆ/ç„¦è™‘æŠ‘åˆ¶.md)**
*   **[æƒ…ç»ªå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[è®¤çŸ¥æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**[\[23\]](#cite_note-23) - è®¸å¤šæœç”¨æ™®ç‘å·´æ—çš„ç”¨æˆ·æè¿°äº†ä¸­åº¦ç”šè‡³å¼ºçƒˆçš„æ¬£å¿«æ„Ÿï¼Œå³ä½¿åœ¨è¾ƒä½å‰‚é‡ä¸‹ä¹Ÿæ˜¯å¦‚æ­¤ã€‚è®¸å¤šç”¨æˆ·å°†å…¶æè¿°ä¸ºç±»ä¼¼äº[é˜¿ç‰‡ç±»è¯ç‰©](./é˜¿ç‰‡ç±»è¯ç‰©.md)å¼•èµ·çš„æ¬£å¿«æ„Ÿã€‚è¿™ç§æ„Ÿè§‰æœ¬èº«å¯ä»¥æè¿°ä¸ºå¼ºçƒˆè€Œå‹å€’æ€§çš„æƒ…æ„Ÿå¹¸ç¦ã€æ»¡è¶³å’Œå¿«ä¹ã€‚
*   **[å»æŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[æ¢¦å¢ƒå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[éŸ³ä¹æ¬£èµå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - æ™®ç‘å·´æ—çš„éŸ³ä¹å¢å¼ºæ•ˆæœå¯ä»¥æè¿°ä¸ºéŸ³ä¹å¬èµ·æ¥æ›´ç»†è‡´ã€â€œæ›´é«˜è´¨é‡â€ï¼Œç”šè‡³åœ¨è¾ƒé«˜å‰‚é‡ä¸‹æ„Ÿè§‰å˜æ…¢äº†ã€‚
*   **[åŠ¨æœºå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - åƒ[å¡ç—›å¶](./å¡ç—›å¶.md)ä¸€æ ·ï¼Œæ™®ç‘å·´æ—å¯èƒ½æœ‰è½»å¾®çš„é•‡é™ä½œç”¨ï¼Œä½†èƒ½ä»¥ç±»ä¼¼[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)çš„æ–¹å¼å¢åŠ åŠ¨æœºã€‚
*   **[æ²‰æµ¸æ„Ÿå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[åˆ›é€ åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - è¿™ç§æ•ˆåº”åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å°¤ä¸ºæ˜æ˜¾ã€‚
*   **[äººæ ¼è§£ä½“](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)** *å’Œ* **[ç°å®è§£ä½“](../è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”%20-%20home.md)** - åœ¨é‡å‰‚é‡ä¸‹ï¼Œæ™®ç‘å·´æ—å¯å¼•èµ·è½»å¾®çš„è§£ç¦»çŠ¶æ€ã€‚æ™®ç‘å·´æ—å¼•èµ·çš„ DPDRï¼ˆäººæ ¼è§£ä½“/ç°å®è§£ä½“ï¼‰å¯èƒ½ä¼šå› ç¡çœ å‰¥å¤ºè€Œå¢åŠ å¹¶å˜å¾—æ›´åŠ *è´Ÿé¢*ï¼ˆçƒ¦èºä¸å®‰ï¼‰ã€‚
*   **[è‡ªæ€æ„å¿µ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - åœ¨é‡å‰‚é‡ä¸‹ï¼Œè¿™å¯èƒ½å¯¼è‡´è‡ªæ€ä¼å›¾ã€‚
*   **[ç²¾ç¥ç—…](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - å³ä½¿åœ¨æ²»ç–—å‰‚é‡ä¸‹ï¼Œæ™®ç‘å·´æ—ä¹Ÿè¢«è¯æ˜åœ¨å°‘æ•°ç”¨æˆ·ä¸­å…·æœ‰ç²¾ç¥ç—…å‰¯ä½œç”¨ [\[24\]](#cite_note-24)[\[25\]](#cite_note-25)ã€‚ç¡çœ å‰¥å¤ºå¼ºçƒˆå¢å¼ºäº†è¿™ç§æ•ˆåº”ï¼Œå¯¹äºé—ä¼ ä¸Šæ˜“æ‚£ç²¾ç¥åˆ†è£‚ç—‡çš„äººæ¥è¯´ï¼Œè¿™ç§é£é™©å¯èƒ½æ›´é«˜ã€‚
*   **[èºç‹‚](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - å½“ç”¨äºæ²»ç–—åŒç›¸æƒ…æ„Ÿéšœç¢æ—¶ [\[26\]](#cite_note-26)ï¼Œå®ƒå¯èƒ½å¯¼è‡´èºç‹‚ï¼Œç”šè‡³åœ¨æ²»ç–—å‰‚é‡ä¸‹ä¹Ÿæ˜¯å¦‚æ­¤ã€‚[\[27\]](#cite_note-27)ã€‚è¿™ç§æ•ˆåº”é€šå¸¸å‘ç”Ÿåœ¨å¨±ä¹ç¯å¢ƒä¸­ã€é‡å‰‚é‡ä¸‹æˆ–ä½¿ç”¨è€…ç¡çœ ä¸è¶³æ—¶ã€‚å®ƒå¯èƒ½è¡¨ç°ä¸ºä½å¼ºåº¦ï¼ˆè½»èºç‹‚ï¼‰æˆ–ä¸[ç²¾ç¥ç—…](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)ååŒä½œç”¨ã€‚ç„¶è€Œï¼Œè¿™ç§æ•ˆåº”å¾ˆå°‘è§ï¼Œå¹¶ä¸æ˜¯å…¸å‹ä½“éªŒçš„ä¸€éƒ¨åˆ†ã€‚
*   **[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**

### **å¬è§‰æ•ˆåº”**

*   **[å¬è§‰å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)**
*   **[å¬è§‰å¤±çœŸ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - è¿™äº›é€šå¸¸å¾ˆè½»å¾®ï¼Œä»…åœ¨æé«˜å‰‚é‡ä¸‹å‡ºç°ã€‚
*   **[å¹»å¬](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - åœ¨è¾ƒé‡å‰‚é‡ä¸‹ï¼Œå¯èƒ½ä¼šç»å†è€³é¸£æˆ–æ„ŸçŸ¥åˆ°æƒ³è±¡çš„å£°éŸ³ï¼Œä¾‹å¦‚äººå£°ã€‚

### **åé—æ•ˆåº”**

æ™®ç‘å·´æ—ä½“éªŒ[æ¶ˆé€€](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)æœŸé—´çš„æ•ˆåº”é€šå¸¸æ˜¯ç§¯æçš„ï¼Œæ›´ç±»ä¼¼äºâ€œä½™è¾‰â€è€Œä¸æ˜¯â€œå®¿é†‰â€ã€‚ä¸[é¡¶å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)æ•ˆåº”ç›¸æ¯”ï¼Œè¿™äº›æ•ˆåº”é€šå¸¸éå¸¸è½»å¾®ã€‚æ™®ç‘å·´æ—çš„åé—æ•ˆåº”åŒ…æ‹¬ï¼š

*   **[åŠ¨æœºå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - æ™®ç‘å·´æ—é€šå¸¸åœ¨ç²¾ç¥ä¸Šå…·æœ‰åˆºæ¿€æ€§ï¼Œ*ä½™è¾‰*ä¹Ÿæ˜¯å¦‚æ­¤ã€‚ç”±äºHighæ„Ÿå¤§éƒ¨åˆ†å·²æ¶ˆå¤±ï¼Œè¿™å¯èƒ½å¯¼è‡´ç”Ÿäº§åŠ›æé«˜ã€‚
*   **[éŸ³ä¹æ¬£èµå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”%20-%20home.md)** - è¿™ç§æ•ˆæœæ²¡æœ‰Highçš„æ—¶å€™é‚£ä¹ˆå¼ºï¼Œä½†éŸ³ä¹æ˜æ˜¾å¢å¼ºï¼Œå¬èµ·æ¥æ›´ç»†è‡´ã€‚
*   **[è‚Œè‚‰æ¾å¼›](../è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)** - è¿™ç§æ•ˆæœæ²¡æœ‰Highçš„æ—¶å€™é‚£ä¹ˆå¼ºï¼Œä½†åœ¨ä½™è¾‰ä¸­ä»ç„¶å­˜åœ¨ã€‚
*   **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](../è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)** - è¿™ç§æ•ˆåº”æ¯”*High*çš„æ—¶å€™å¼±ï¼Œä½†ç”¨æˆ·ä»ç„¶å¯ä»¥æ³¨æ„åˆ°ã€‚åœ¨*ä½™è¾‰* / ä¸‹é™æœŸé©¾é©¶æ˜¯ä¸ªåä¸»æ„ã€‚
*   **[å¤´æ™•](../è¯æ•ˆ/å¤´æ™•.md)** - æ™®ç‘å·´æ—çš„åé—æ•ˆåº”ä¸»è¦æ˜¯ç§¯æçš„ï¼Œä½†å¤´æ™•ä»ç„¶å¯èƒ½å­˜åœ¨ï¼Œç‰¹åˆ«æ˜¯åœ¨æœç”¨é«˜å‰‚é‡åã€‚

### ä½“éªŒæŠ¥å‘Š

æè¿°è¯¥åŒ–åˆç‰©åœ¨æˆ‘ä»¬[ä½“éªŒç´¢å¼•](../æ–‡æ¡£/ä½“éªŒç´¢å¼•.md)ä¸­çš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

*   [Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening](../æ–‡æ¡£/Experience:225mg_Pregabalin_+Cannabis_-Bliss_and_Serenity;_a_hedonistic_evening.md)
*   [Experience:50mg Pregabalin - Surprisingly strong](../æ–‡æ¡£/Experience:50mg_Pregabalin_-_Surprisingly_strong.md)
*   [Experience:Pregabalin (2,625 mg, oral) - Pharmaceutical Sunshine](../æ–‡æ¡£/Experience:Pregabalin_(2,625_mg,_oral)_-_Pharmaceutical_Sunshine.md)
*   [Experience:Pregabalin (450mg, oral) + Methylphenidate (20mg, oral) - Gaba Flipping](../æ–‡æ¡£/Experience:Pregabalin_(450mg,_oral)_+_Methylphenidate_(20mg,_oral)_-_Gaba_Flipping.md)

å¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šï¼š

*   [Erowid Experience Vaults: Pregabalin](https://www.erowid.org/experiences/subs/exp_Pharms_Pregabalin.shtml)

## åŒ»ç–—ç”¨é€”

æ™®ç‘å·´æ—ç”¨äºåŒ»ç–—ç¯å¢ƒï¼Œé€šå¸¸ä»¥èƒ¶å›Šå½¢å¼å¤„æ–¹ï¼Œç”¨äºæ²»ç–—ç™«ç—«ã€ç¥ç»æ€§ç–¼ç—›ã€çº¤ç»´è‚Œç—›å’Œå¹¿æ³›æ€§ç„¦è™‘ç—‡ã€‚å®ƒç”¨äºç™«ç—«æ˜¯ä½œä¸ºæˆäººéƒ¨åˆ†æ€§ç™«ç—«å‘ä½œï¼ˆä¼´æˆ–ä¸ä¼´ç»§å‘æ€§å…¨èº«åŒ–ï¼‰çš„æ·»åŠ ç–—æ³•ã€‚æ™®ç‘å·´æ—çš„ä¸€äº›è¶…è¯´æ˜ä¹¦ç”¨é€”åŒ…æ‹¬ä¸å®è…¿ç»¼åˆå¾ã€é¢„é˜²åå¤´ç—›ã€ç¤¾äº¤ç„¦è™‘ç—‡å’Œé…’ç²¾æˆ’æ–­ã€‚

### ç™«ç—«é¢„é˜²

å½“å…¶ä»–æ²»ç–—æ— æ³•æ§åˆ¶éƒ¨åˆ†æ€§ç™«ç—«æ—¶ï¼Œæ·»åŠ æ™®ç‘å·´æ—æ˜¯æœ‰ç”¨çš„ã€‚å®ƒå•ç‹¬ä½¿ç”¨çš„æ•ˆæœä¸å¦‚å…¶ä»–ä¸€äº›ç™«ç—«è¯ç‰©ã€‚ç›®å‰å°šä¸æ¸…æ¥šå®ƒåœ¨è¿™æ–¹é¢ä¸åŠ å·´å–·ä¸ç›¸æ¯”å¦‚ä½•ã€‚æ™®ç‘å·´æ—ä¹Ÿè¢«è¯æ˜å¯¹é…’ç²¾æˆ’æ–­å¼•èµ·çš„ç™«ç—«å‘ä½œæœ‰æ•ˆ [\[28\]](#cite_note-28)ã€‚

### ç¥ç»æ€§ç–¼ç—›

æ¬§æ´²ç¥ç»å­¦ä¼šè”ç›Ÿå»ºè®®æ™®ç‘å·´æ—ä½œä¸ºæ²»ç–—ç³–å°¿ç—…ç¥ç»ç—…å˜ã€å¸¦çŠ¶ç–±ç–¹åç¥ç»ç—›å’Œä¸­æ¢ç¥ç»æ€§ç–¼ç—›ç›¸å…³ç–¼ç—›çš„ä¸€çº¿è¯ç‰©ã€‚å°‘æ•°äººè·å¾—å®è´¨æ€§ç›Šå¤„ï¼Œè¾ƒå¤šäººè·å¾—ä¸­åº¦ç›Šå¤„ã€‚å…¶ä»–ä¸€çº¿è¯ç‰©ï¼ŒåŒ…æ‹¬åŠ å·´å–·ä¸å’Œä¸‰ç¯ç±»æŠ—æŠ‘éƒè¯ï¼Œè¢«ç»™äºˆåŒç­‰çš„ä¸€çº¿è¯ç‰©æƒé‡ï¼Œè€Œä¸”ä¸æ™®ç‘å·´æ—ä¸åŒï¼Œå®ƒä»¬æœ‰æ›´ä¾¿å®œçš„ä»¿åˆ¶è¯ã€‚

### ç„¦è™‘ç—‡

ä¸–ç•Œç”Ÿç‰©ç²¾ç¥ç—…å­¦è”åˆä¼šå»ºè®®æ™®ç‘å·´æ—ä½œä¸ºæ²»ç–—å¹¿æ³›æ€§ç„¦è™‘ç—‡çš„å‡ ç§ä¸€çº¿è¯ç‰©ä¹‹ä¸€ï¼Œä½†å»ºè®®å…¶ä»–è¯ç‰©å¦‚ SSRIs ä½œä¸ºå¼ºè¿«ç—‡å’Œåˆ›ä¼¤ååº”æ¿€éšœç¢çš„ä¸€çº¿æ²»ç–—ã€‚å®ƒä¼¼ä¹å…·æœ‰ç±»ä¼¼äºè‹¯äºŒæ°®å“ç±»è¯ç‰©çš„æŠ—ç„¦è™‘ä½œç”¨ï¼Œä½†ä¾èµ–é£é™©è¾ƒä½ã€‚

æ™®ç‘å·´æ—çš„èµ·æ•ˆåœ¨ä½¿ç”¨ 1 å‘¨åå‡ºç°ï¼Œå…¶æœ‰æ•ˆæ€§ç±»ä¼¼äºåŠ³æ‹‰è¥¿æ³®ã€é˜¿æ™®å”‘ä»‘å’Œæ–‡æ‹‰æ³•è¾›ï¼Œä½†æ™®ç‘å·´æ—é€šè¿‡å¯¹å¿ƒèº«ç„¦è™‘ç—‡çŠ¶äº§ç”Ÿæ›´ä¸€è‡´çš„æ²»ç–—æ•ˆæœè€Œæ˜¾ç¤ºå‡ºä¼˜åŠ¿ã€‚é•¿æœŸè¯•éªŒè¡¨æ˜å…¶æŒç»­æœ‰æ•ˆï¼Œä¸”æœªäº§ç”Ÿè€å—æ€§ï¼Œæ­¤å¤–ï¼Œä¸è‹¯äºŒæ°®å“ç±»è¯ç‰©ä¸åŒï¼Œå®ƒå¯¹ç¡çœ å’Œç¡çœ ç»“æ„æœ‰æœ‰ç›Šä½œç”¨ï¼Œå…¶ç‰¹å¾æ˜¯å¢å¼ºæ…¢æ³¢ç¡çœ ã€‚ä¸è¿™äº›è¯ç‰©ç›¸æ¯”ï¼Œå®ƒäº§ç”Ÿçš„è®¤çŸ¥å’Œç²¾ç¥è¿åŠ¨éšœç¢è¾ƒè½»ï¼Œå‡ºäºè¿™äº›åŸå› ï¼Œå¯èƒ½ä¼˜äºè‹¯äºŒæ°®å“ç±»è¯ç‰©ã€‚

### ç‰©è´¨ä½¿ç”¨éšœç¢

#### é˜¿ç‰‡ç±»è¯ç‰©

å­˜åœ¨é€šè¿‡è¡¥å……æ™®ç‘å·´æ—æˆåŠŸåœæ­¢[é˜¿ç‰‡ç±»è¯ç‰©](./é˜¿ç‰‡ç±»è¯ç‰©.md)ä½¿ç”¨çš„è½¶äº‹æŠ¥å‘Š[\[29\]](#cite_note-29)ã€‚

#### çƒŸè‰

ä¸€é¡¹ä¸ºæœŸå››å¤©çš„å®‰æ…°å‰‚å¯¹ç…§è¯•éªŒï¼ˆn=24 å®Œæˆï¼‰è°ƒæŸ¥äº†æ™®ç‘å·´æ—å¯¹éå¯»æ±‚æ²»ç–—å¸çƒŸè€…æˆ’çƒŸçš„å½±å“ã€‚[\[30\]](#cite_note-30) è¯¥ç ”ç©¶æœªå‘ç°å¯¹å¸çƒŸè¡Œä¸ºæœ‰ä»»ä½•ç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å½±å“ï¼Œå°½ç®¡æ™®ç‘å·´æ—å‡å°‘äº†ä¸€äº›æˆ’æ–­ç—‡çŠ¶ï¼šç„¦è™‘ã€æ˜“æ€’å’Œæ²®ä¸§ã€‚æ™®ç‘å·´æ—è¿˜é™ä½äº†å¸çƒŸåçš„ä¸»è§‚â€œå–œçˆ±â€ç¨‹åº¦ã€‚

#### é…’ç²¾

ä¸€é¡¹å…³äºä½¿ç”¨æ™®ç‘å·´æ—æ²»ç–—é…’ç²¾ä¸­æ¯’æˆ–é…’ç²¾æˆ’æ–­çš„äº”é¡¹ç ”ç©¶çš„èŸèƒåˆ†æå‘ç°ï¼Œåœ¨ 150-450 æ¯«å…‹/å¤©çš„å‰‚é‡ä¸‹ï¼Œå¯¹æ¸…é†’æ‚£è€…çš„å¤å‘é¢„é˜²æœ‰ç§¯æç»“æœï¼Œä½†åœ¨æ²»ç–—æ€¥æ€§é…’ç²¾æˆ’æ–­æ–¹é¢çš„ç»“æœç›¸äº’çŸ›ç›¾ã€‚[\[31\]](#cite_note-31) å…¶ä¸­ä¸¤é¡¹ç ”ç©¶ä»…æ¶‰åŠç»´æŒæˆ’é…’ã€‚ä¸¤è€…éƒ½æ˜¾ç¤ºäº†ç§¯æçš„ç»“æœã€‚åœ¨å…¶ä¸­ä¸€é¡¹ï¼ˆn=59ï¼‰ä¸­ï¼Œæ™®ç‘å·´æ—åœ¨ä»»ä½•é‡é…’ç²¾çš„æˆ’æ–­å¤©æ•°æŒ‡æ ‡ä¸Šä¼˜äºçº³æ›²é…®ã€‚

#### è‹¯äºŒæ°®å“ç±»

ä¸€é¡¹é’ˆå¯¹ 15 åé«˜å‰‚é‡[è‹¯äºŒæ°®å“ç±»](./è‹¯äºŒæ°®å“ç±».md)ä¾èµ–è€…çš„å¼€æ”¾æ ‡ç­¾è¯•ç‚¹ç ”ç©¶[\[32\]](#cite_note-32)æŠ¥å‘Šç§°ï¼Œæ‰€æœ‰å—è¯•è€…åœ¨æœç”¨ 225-900 æ¯«å…‹/å¤©æ™®ç‘å·´æ—è¡¥å……å‰‚é‡çš„æƒ…å†µä¸‹ï¼Œéƒ½åœ¨ 14 å‘¨å†…æˆåŠŸåœæ­¢äº†è‹¯äºŒæ°®å“ç±»è¯ç‰©ã€‚æ‚£è€…è¿˜è¡¨ç°å‡ºç„¦è™‘æ°´å¹³é™ä½å’Œè®¤çŸ¥åŠŸèƒ½æ”¹å–„ã€‚æ™®ç‘å·´æ—è€å—æ€§è‰¯å¥½ã€‚

## æ¯’æ€§å’Œæ½œåœ¨å±å®³

ç›¸å¯¹äºå‰‚é‡ï¼Œæ™®ç‘å·´æ—çš„æ¯’æ€§å¯èƒ½è¾ƒä½ã€‚ç„¶è€Œï¼Œå½“ä¸[é…’ç²¾](./é…’ç²¾.md)æˆ–[é˜¿ç‰‡ç±»è¯ç‰©](./é˜¿ç‰‡ç±»è¯ç‰©.md)ç­‰[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)æ··åˆä½¿ç”¨æ—¶ï¼Œå®ƒå…·æœ‰æ½œåœ¨çš„[è‡´æ­»æ€§](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚

### ç™«ç—«é£é™©

æ™®ç‘å·´æ—å·²è¢«è¯æ˜åœ¨å¨±ä¹å‰‚é‡ä¸‹ä¼šè¯±å‘å’Œ/æˆ–å¢åŠ ç™«ç—«å‘ä½œçš„é£é™©ã€‚[\[33\]](#cite_note-33)[\[34\]](#cite_note-34)[\[35\]](#cite_note-35) å‡ ä¹æ²¡æœ‰è¯æ®è¡¨æ˜åœ¨åŒ»ç–—å‰‚é‡ï¼ˆ600mgåŠä»¥ä¸‹ï¼‰ä¸‹å­˜åœ¨æ‹…å¿§ã€‚å½“ä¸å…¶ä»–é™ä½ç™«ç—«é˜ˆå€¼çš„è¯ç‰©æ··åˆä½¿ç”¨æ—¶ï¼Œè¿™ç§é£é™©å¯èƒ½ä¼šå¢åŠ ã€‚å»ºè®®åœ¨ä½¿ç”¨é«˜äº 600mg çš„å‰‚é‡æ—¶è°¨æ…ã€‚å‡å°‘å„ç§æ˜“æ„Ÿå› ç´ ä¹Ÿå¯èƒ½æœ‰ç›Šäºé™ä½è¿™ç§é£é™©ã€‚æ˜“æ„Ÿå› ç´ å¯èƒ½åŒ…æ‹¬ä½é’ ã€ç¡çœ ä¸è¶³å’Œå‰§çƒˆä½“åŠ›æ´»åŠ¨ç­‰ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¯¥ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/è´Ÿè´£ä»»çš„è¯ç‰©ä½¿ç”¨.md)ã€‚

### è‡´æ­»å‰‚é‡

å•®é½¿åŠ¨ç‰©çš„[LD50](../æ–‡æ¡£/LD50.md)å·²ç¡®å®šå¤§äº 5000mg/kgã€‚å¤§é¼ é™è„‰æ³¨å°„ LD50 ä¹Ÿè¢«ç¡®å®šä¸ºå¤§äº 300mg/kgã€‚[\[36\]](#cite_note-36)

å°±äººç±»è€Œè¨€ï¼Œæœ‰ä¸€ä¸ªæ¡ˆä¾‹æŠ¥å‘Šç§°ï¼Œä¸€åç”·å­æœç”¨äº† 8,400mg æ™®ç‘å·´æ—å¹¶æœ€ç»ˆé™·å…¥æ˜è¿·ï¼Œä½†ä»…é€šè¿‡æ”¯æŒæ€§æŠ¤ç†è¿›è¡Œç®¡ç†ï¼Œç›´åˆ°ä»–æ¢å¤æ„è¯†ã€‚[\[37\]](#cite_note-37) ç›¸æ¯”ä¹‹ä¸‹ï¼Œæ™®ç‘å·´æ—çš„æœ€å¤§æ¨èæ²»ç–—å‰‚é‡ä¸º 600mg/å¤©ã€‚[\[38\]](#cite_note-38) è¾‰ç‘å…¬å¸å…³äº Lyrica çš„å®˜æ–¹è¯´æ˜ä¹¦æŒ‡å‡ºï¼Œä¸´åºŠè¯•éªŒæœŸé—´æ„å¤–æ‘„å…¥æ™®ç‘å·´æ—çš„æœ€é«˜å‰‚é‡ä¸º 8 å…‹ï¼Œæœªäº§ç”Ÿä¸¥é‡åæœã€‚[\[39\]](#cite_note-39)

### è€å—æ€§å’Œæˆç˜¾æ½œåŠ›

æ™®ç‘å·´æ—æœ€åˆè¢«è®¤ä¸ºæ˜¯éæˆç˜¾æ€§çš„ï¼Œæ»¥ç”¨æ½œåŠ›ä½ï¼Œå‡ ä¹ä¸äº§ç”Ÿè€å—æ€§ã€‚ç„¶è€Œï¼Œè¯¥ç‰©è´¨çš„å¨±ä¹æ€§ä½¿ç”¨å¯¼è‡´äº†å¯¹è¿™ä¸€è¯„ä¼°çš„é‡æ–°è¯„ä¼°ã€‚è¯¥ç‰©è´¨çš„æ¬£å¿«ä½œç”¨å’Œè€å—æ€§çš„å‘å±•å¯èƒ½å¯¼è‡´ä½¿ç”¨è¿œé«˜äºæ²»ç–—èŒƒå›´çš„å‰‚é‡ï¼Œè¿™è¡¨æ˜äº†å¨±ä¹æ€§ä½¿ç”¨å’Œæˆç˜¾çš„æ½œåŠ›ã€‚[\[40\]](#cite_note-40)[\[41\]](#cite_note-41)

è¿ç»­ä½¿ç”¨å‡ ä¸ªæœˆå†…ä¼šå¯¹æŠ‘åˆ¶ä½œç”¨äº§ç”Ÿè€å—æ€§ã€‚åœæ­¢ä½¿ç”¨åï¼Œè€å—æ€§ä¼šåœ¨ 7 - 14 å¤©å†…æ¢å¤åˆ°åŸºçº¿ã€‚åœ¨æŒç»­ç»™è¯å‡ ä¸ªæœˆæˆ–æ›´é•¿æ—¶é—´åçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æˆ’æ–­ç—‡çŠ¶æˆ–åå¼¹ç—‡çŠ¶ï¼Œå¹¶å¯èƒ½éœ€è¦é€æ¸å‡é‡ã€‚

çªç„¶åœæ­¢é•¿æœŸä½¿ç”¨çš„æˆ’æ–­ååº”åŒ…æ‹¬ç„¦è™‘ã€å¤±çœ ã€å‡ºæ±—ã€è‚Œè‚‰ç—‰æŒ›ã€èƒƒè‚ é“é—®é¢˜ã€æ½®çƒ­å’Œå‘å†·ã€æ¶å¿ƒä»¥åŠæµæ„Ÿæ ·æ„Ÿè§‰ã€‚

### ç›¸äº’ä½œç”¨

æœ‰ä¸€ä»½æŠ¥å‘Šç§°ï¼Œä¸€åæ‚£è€…åœ¨å›´æ‰‹æœ¯æœŸä½¿ç”¨ç¾Ÿè€ƒé…®å’Œæ™®ç‘å·´æ—åå‡ºç°è¡€æ¸…ç´ ç»¼åˆå¾ã€‚[\[42\]](#cite_note-42) ç„¶è€Œï¼Œå‡ é¡¹ç ”ç©¶æœªèƒ½å‘ç°æ™®ç‘å·´æ—æœ‰ä»»ä½•è¡€æ¸…ç´ èƒ½æ•ˆåº”ã€‚ä¸€ç¯‡è®ºæ–‡æŒ‡å‡ºï¼Œâ€œè™½ç„¶æ™®ç‘å·´æ—æ˜¯ GABA çš„ç»“æ„ç±»ä¼¼ç‰©ï¼Œä½†å®ƒåœ¨ GABA-A æˆ– GABA-B å—ä½“ä¸Šæ²¡æœ‰ä¸´åºŠæ˜¾ç€ä½œç”¨ï¼Œä¹Ÿä¸ä¼šåœ¨ä»£è°¢ä¸Šè½¬åŒ–ä¸º GABA æˆ– GABA æ¿€åŠ¨å‰‚ã€‚æ™®ç‘å·´æ—ä¸æ˜¯è¡€æ¸…ç´ å†æ‘„å–æŠ‘åˆ¶å‰‚ï¼Œä¹Ÿä¸ä½œä¸ºè°·æ°¨é…¸å—ä½“æ‹®æŠ—å‰‚èµ·ä½œç”¨ã€‚â€[\[43\]](#cite_note-43) ä¸€é¡¹è¾ƒæ–°çš„ç ”ç©¶å†™é“ï¼Œâ€œæ™®ç‘å·´æ—ä¸è¡€æ¸…ç´ å’Œå¤šå·´èƒºå—ä½“æ— å…³ï¼Œä¸æŠ‘åˆ¶å¤šå·´èƒºã€è¡€æ¸…ç´ æˆ–å»ç”²è‚¾ä¸Šè…ºç´ çš„å†æ‘„å–ã€‚â€[\[44\]](#cite_note-44) æ™®ç‘å·´æ—çš„ä¸»è¦ä½œç”¨æœºåˆ¶æ˜¯ç»“åˆå¹¶é˜»æ–­ç”µå‹é—¨æ§é’™é€šé“ä¸Šçš„äºšå—ä½“ï¼Œå¯¼è‡´ä¸‹æ¸¸è¿‡åº¦æ´»è·ƒç¥ç»å…ƒçš„å‡å°‘ã€‚

å¦‚æœæ™®ç‘å·´æ—å…·æœ‰[è¡€æ¸…ç´ èƒ½](./è¡€æ¸…ç´ .md)æ•ˆåº”ï¼Œå®ƒå¯èƒ½ä¼šä¸å…¶ä»–è¡€æ¸…ç´ èƒ½ç‰©è´¨äº§ç”Ÿè´Ÿé¢ç›¸äº’ä½œç”¨ï¼ŒåŒ…æ‹¬ SSRIsã€MDMAã€å„ç§é•‡ç—›è¯ä»¥åŠå¯èƒ½çš„å…¶ä»–å¨±ä¹å’ŒåŒ»ç–—ç‰©è´¨ã€‚é‰´äºå¤šé¡¹ç ”ç©¶å®Œå…¨ç¼ºä¹ä»»ä½•è¡€æ¸…ç´ èƒ½æ´»æ€§çš„è¯æ®ï¼Œé‚£ä¸€èµ·æŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶ä¼¼ä¹å¯èƒ½æ˜¯ä¸€æ¬¡ç”±æœªçŸ¥å› ç´ å¼•èµ·çš„æ„å¤–äº‹æ•…ã€‚

## æ³•å¾‹åœ°ä½

æ™®ç‘å·´æ—åœ¨å¤§å¤šæ•°å›½å®¶è¢«ä½œä¸ºå¤„æ–¹è¯ç›‘ç®¡ã€‚

*   **å¾·å›½ï¼š** æ ¹æ® Anlage 1 AMVVï¼Œæ™®ç‘å·´æ—æ˜¯ä¸€ç§å¤„æ–¹è¯ã€‚[\[45\]](#cite_note-45)
*   **æŒªå¨ï¼š** æ™®ç‘å·´æ—ä¸å¤§å¤šæ•°è‹¯äºŒæ°®å“ç±»è¯ç‰©å’Œæ­¢ç—›è¯ä¸€èµ·è¢«åˆ—å…¥å¤„æ–¹é™„è¡¨ Bã€‚ç”±äºæŠ¥å‘Šçš„å¨±ä¹æ€§ä½¿ç”¨ã€è€å—æ€§å‘å±•å’Œæˆç˜¾ï¼Œå®ƒä»é™åˆ¶è¾ƒå°‘çš„é™„è¡¨ C é‡æ–°å®‰æ’åˆ°é™„è¡¨ Bã€‚[\[46\]](#cite_note-46)
*   **ç‘å…¸ï¼š** æ™®ç‘å·´æ—æ˜¯ä¸€ç§å¤„æ–¹è¯ã€‚è‡ª 2018 å¹´ 7 æœˆ 24 æ—¥èµ·è¢«å½’ç±»ä¸ºå—æ§ç‰©è´¨ï¼ˆé™„è¡¨ V è¯ç‰©ï¼‰ã€‚[\[47\]](#cite_note-47)
*   **ç‘å£«ï¼š** æ™®ç‘å·´æ—è¢«åˆ—ä¸º "Abgabekategorie B" è¯ç‰©ï¼Œéœ€è¦å¤„æ–¹ã€‚\[*[æ¥æºè¯·æ±‚](../æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
*   **åœŸè€³å…¶**ï¼šæ™®ç‘å·´æ—æ˜¯ä¸€ç§ä»…é™â€œç»¿è‰²å¤„æ–¹â€çš„ç‰©è´¨[\[48\]](#cite_note-48)ï¼Œåœ¨æ²¡æœ‰å¤„æ–¹çš„æƒ…å†µä¸‹é”€å”®æˆ–æ‹¥æœ‰æ˜¯éæ³•çš„ã€‚\[*[æ¥æºè¯·æ±‚](../æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
*   **è‹±å›½ï¼š** ã€Š1971 å¹´æ»¥ç”¨è¯ç‰©æ³•ã€‹è§„å®šï¼Œæ²¡æœ‰å¤„æ–¹æ‹¥æœ‰è¯¥è¯ç‰©æ˜¯éæ³•çš„ï¼Œä¸ºæ­¤ç›®çš„ï¼Œå®ƒè¢«å½’ç±»ä¸º C ç±»è¯ç‰©ã€‚[\[49\]](#cite_note-49)
*   **ç¾å›½ï¼š** æ™®ç‘å·´æ—åœ¨é™„è¡¨ V ä¸­ï¼Œè¡¨æ˜â€œæ»¥ç”¨æ½œåŠ›ä½â€ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œè‹¯äºŒæ°®å“ç±»è¯ç‰©åœ¨é™„è¡¨ IV ä¸­ã€‚[\[50\]](#cite_note-50)

## å¦è§

*   [è´Ÿè´£ä»»çš„è¯ç‰©ä½¿ç”¨](../æ–‡æ¡£/è´Ÿè´£ä»»çš„è¯ç‰©ä½¿ç”¨.md)
*   [åŠ å·´å–·ä¸](./åŠ å·´å–·ä¸.md)
*   [è‹¯äºŒæ°®å“ç±»](./è‹¯äºŒæ°®å“ç±».md)

## å¤–éƒ¨é“¾æ¥

*   [Pregabalin (Wikipedia)](https://en.wikipedia.org/wiki/Pregabalin)
*   [Pregabalin (Erowid Vault)](https://www.erowid.org/pharms/pregabalin/)
*   [Pregabalin (TiHKAL / Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=1909)
*   [Pregabalin (Drugs.com)](http://web.archive.org/web/20160508222204/http://www.drugs.com/cdi/pregabalin.html)

## æ–‡çŒ®

*   Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T., â€¦ Williams, D. (2006). Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proceedings of the National Academy of Sciences of the United States of America, 103(46), 17537â€“42. <https://doi.org/10.1073/pnas.0409066103>
*   Eroglu, Ã‡., Allen, N. J., Susman, M. W., Oâ€™Rourke, N. A., Park, C. Y., Ã–zkan, E., â€¦ Barres, B. A. (2009). Gabapentin Receptor Î±2Î´-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis. Cell, 139(2), 380â€“392. <https://doi.org/10.1016/j.cell.2009.09.025>
*   Taylor, C. P., Angelotti, T., & Fauman, E. (2007). Pharmacology and mechanism of action of pregabalin: The calcium channel ??2-?? (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research, 73(2), 137â€“150. <https://doi.org/10.1016/j.eplepsyres.2006.09.008>
*   Hindmarch, I., Dawson, J., & Stanley, N. (2005). A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep, 28(2), 187â€“93. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/16171242>
*   Wood, D. M., Berry, D. J., Glover, G., Eastwood, J., & Dargan, P. I. (2010). Significant Pregabalin Toxicity Managed with Supportive Care Alone. Journal of Medical Toxicology, 6(4), 435â€“437. <https://doi.org/10.1007/s13181-010-0052-3>
*   Braga, A. J., & Chidley, K. (2007). Self-poisoning with lamotrigine and pregabalin. Anaesthesia, 62(5), 524â€“527. <https://doi.org/10.1111/j.1365-2044.2006.04913.x>
*   Kavoussi, R. (2006). Pregabalin: From molecule to medicine. European Neuropsychopharmacology, 16, S128â€“S133. <https://doi.org/10.1016/j.euroneuro.2006.04.005>
*   Song, H.-K. (2013). Serotonin syndrome with perioperative oxycodone and pregabalin. Pain Physician, 16(October), E632-3. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/24077214>
*   Herman, A. I., Waters, A. J., McKee, S. A., & Sofuoglu, M. (2012). Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology, 220(3), 611â€“617. <https://doi.org/10.1007/s00213-011-2507-x>
*   Guglielmo, R., Martinotti, G., Clerici, M., & Janiri, L. (2012). Pregabalin for alcohol dependence: A critical review of the literature. Advances in Therapy, 29(11), 947â€“957. <https://doi.org/10.1007/s12325-012-0061-5>
*   KÃ¤mmerer, N., Lemenager, T., Grosshans, M., Kiefer, F., & Hermann, D. (2012). [Pregabalin for the reduction of opiate withdrawal symptoms]. Psychiatrische Praxis, 39(7), 351â€“2. <https://doi.org/10.1055/s-0032-1305042>
*   Bobes, J., Rubio, G., TerÃ¡n, A., Cervera, G., LÃ³pez-GÃ³mez, V., Vilardaga, I., & PÃ©rez, M. (2012). Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice. European Psychiatry, 27(4), 301â€“307. <https://doi.org/10.1016/j.eurpsy.2010.12.004>
*   Oulis, P., Konstantakopoulos, G., Kouzoupis, A. V., Masdrakis, V. G., Karakatsanis, N. A., Karapoulios, E., â€¦ Papadimitriou, G. N. (2008). Pregabalin in the discontinuation of long-term benzodiazepinesâ€™ use. Human Psychopharmacology: Clinical and Experimental, 23(4), 337â€“340. <https://doi.org/10.1002/hup.937>

## å‚è€ƒæ–‡çŒ®

1.  [â†‘](#cite_ref-tripsit_1-0) [*Risks of Combining Depressants - TripSit*](https://tripsit.me/combining-depressants/)
2.  [â†‘](#cite_ref-Bockbrader2010_2-0) Bockbrader, H. N., Radulovic, L. L., Posvar, E. L., Strand, J. C., Alvey, C. W., Busch, J. A., Randinitis, E. J., Corrigan, B. W., Haig, G. M., Boyd, R. A., Wesche, D. L. (August 2010). ["Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers"](http://doi.wiley.com/10.1177/0091270009352087). *The Journal of Clinical Pharmacology*. **50** (8): 941â€“950. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1177/0091270009352087](//doi.org/10.1177%2F0091270009352087). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0091-2700](//www.worldcat.org/issn/0091-2700).
3.  [â†‘](#cite_ref-3) EMA (2018), [*Lyrica*](https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica)
4.  [â†‘](#cite_ref-4) Garcia-Borreguero, D., Larrosa, O., Williams, A.-M., Albares, J., Pascual, M., Palacios, J. C., Fernandez, C. (8 June 2010). ["Treatment of restless legs syndrome with pregabalin: A double-blind, placebo-controlled study"](https://n.neurology.org/content/74/23/1897). *Neurology*. **74** (23): 1897â€“1904. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1212/WNL.0b013e3181e1ce73](//doi.org/10.1212%2FWNL.0b013e3181e1ce73). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0028-3878](//www.worldcat.org/issn/0028-3878).
5.  [â†‘](#cite_ref-5) Wesche, D., Bockbrader, H. (March 2005). ["A pharmacokinetic comparison of pregabalin and gabapentin"](https://linkinghub.elsevier.com/retrieve/pii/S152659000500129X). *The Journal of Pain*. **6** (3): S29. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.jpain.2005.01.114](//doi.org/10.1016%2Fj.jpain.2005.01.114). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1526-5900](//www.worldcat.org/issn/1526-5900).
6.  [â†‘](#cite_ref-6) Feltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., Pande, A. C. (June 2003). ["A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients With Generalized Anxiety Disorder:"](http://journals.lww.com/00004714-200306000-00005). *Journal of Clinical Psychopharmacology*. **23** (3): 240â€“249. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1097/01.jcp.0000084032.22282.ff](//doi.org/10.1097%2F01.jcp.0000084032.22282.ff). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0271-0749](//www.worldcat.org/issn/0271-0749).
7.  [â†‘](#cite_ref-7) Pande, A. C., Pollack, M. H., Crockatt, J., Greiner, M., Chouinard, G., Lydiard, R. B., Taylor, C. B., Dager, S. R., Shiovitz, T. (August 2000). ["Placebo-Controlled Study of Gabapentin Treatment of Panic Disorder:"](http://journals.lww.com/00004714-200008000-00011). *Journal of Clinical Psychopharmacology*. **20** (4): 467â€“471. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1097/00004714-200008000-00011](//doi.org/10.1097%2F00004714-200008000-00011). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0271-0749](//www.worldcat.org/issn/0271-0749).
8.  [â†‘](#cite_ref-8) Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T.-Z., Bramwell, S., Corradini, L., England, S., Winks, J., Kinloch, R. A., Hendrich, J., Dolphin, A. C., Webb, T., Williams, D. (14 November 2006). ["Identification of the Î± 2 -Î´-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin"](https://pnas.org/doi/full/10.1073/pnas.0409066103). *Proceedings of the National Academy of Sciences*. **103** (46): 17537â€“17542. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1073/pnas.0409066103](//doi.org/10.1073%2Fpnas.0409066103). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0027-8424](//www.worldcat.org/issn/0027-8424).
9.  â†‘ [9.0](#cite_ref-thromb_9-0) [9.1](#cite_ref-thromb_9-1) Eroglu, Ã‡., Allen, N. J., Susman, M. W., Oâ€™Rourke, N. A., Park, C. Y., Ã–zkan, E., Chakraborty, C., Mulinyawe, S. B., Annis, D. S., Huberman, A. D., Green, E. M., Lawler, J., Dolmetsch, R., Garcia, K. C., Smith, S. J., Luo, Z. D., Rosenthal, A., Mosher, D. F., Barres, B. A. (October 2009). ["Gabapentin Receptor Î±2Î´-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis"](https://linkinghub.elsevier.com/retrieve/pii/S0092867409011854). *Cell*. **139** (2): 380â€“392. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.cell.2009.09.025](//doi.org/10.1016%2Fj.cell.2009.09.025). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0092-8674](//www.worldcat.org/issn/0092-8674).
10. [â†‘](#cite_ref-10) Taylor, C. P., Angelotti, T., Fauman, E. (February 2007). ["Pharmacology and mechanism of action of pregabalin: The calcium channel Î±2â€“Î´ (alpha2â€“delta) subunit as a target for antiepileptic drug discovery"](https://linkinghub.elsevier.com/retrieve/pii/S0920121106003895). *Epilepsy Research*. **73** (2): 137â€“150. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.eplepsyres.2006.09.008](//doi.org/10.1016%2Fj.eplepsyres.2006.09.008). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0920-1211](//www.worldcat.org/issn/0920-1211).
11. [â†‘](#cite_ref-11) Micheva, Kristina D.; Taylor, Charles P.; Smith, Stephen J. (2006-08-01). ["Pregabalin Reduces the Release of Synaptic Vesicles from Cultured Hippocampal Neurons"](https://molpharm.aspetjournals.org/content/70/2/467). *Molecular Pharmacology*. **70** (2): 467â€“476. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1124/mol.106.023309](//doi.org/10.1124%2Fmol.106.023309). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1521-0111](//www.worldcat.org/issn/1521-0111). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [16641316](//www.ncbi.nlm.nih.gov/pubmed/16641316). Retrieved 2023-07-14.
12. [â†‘](#cite_ref-12) Hindmarch, I., Dawson, J., Stanley, N. (February 2005). "A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo". *Sleep*. **28** (2): 187â€“193. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/sleep/28.2.187](//doi.org/10.1093%2Fsleep%2F28.2.187). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0161-8105](//www.worldcat.org/issn/0161-8105).
13. [â†‘](#cite_ref-13) <https://www.drugs.com/ppa/pregabalin.html>
14. [â†‘](#cite_ref-14) <http://web.archive.org/web/20160305012454/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000546/WC500046602.pdf>
15. [â†‘](#cite_ref-15) [*LYRICA 200 mg*](http://web.archive.org/web/20160305071130/http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=41099), 2016
16. [â†‘](#cite_ref-16) [*Pregabalin*](https://go.drugbank.com/drugs/DB00230)
17. [â†‘](#cite_ref-17) Arnold, L. M., Emir, B., Pauer, L., Resnick, M., Clair, A. (January 2015). "Time to improvement of pain and sleep quality in clinical trials of pregabalin for the treatment of fibromyalgia". *Pain Medicine (Malden, Mass.)*. **16** (1): 176â€“185. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/pme.12636](//doi.org/10.1111%2Fpme.12636). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1526-4637](//www.worldcat.org/issn/1526-4637).
18. [â†‘](#cite_ref-18) Perez-Lloret, S., Rojas, G. M., Menoni, M. C., Ruiz, G., VelÃ¡squez, C., Rodriguez, H., Rey, M. V., Cardinali, A. D. P., PGB Study Team (February 2012). "Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course". *Clinical Neuropharmacology*. **35** (1): 21â€“24. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1097/WNF.0b013e31823df2dc](//doi.org/10.1097%2FWNF.0b013e31823df2dc). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1537-162X](//www.worldcat.org/issn/1537-162X).
19. [â†‘](#cite_ref-19) Verma, V., Singh, N., Singh Jaggi, A. (January 2014). ["Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915349/). *Current Neuropharmacology*. **12** (1): 44â€“56. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.2174/1570159X1201140117162802](//doi.org/10.2174%2F1570159X1201140117162802). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1570-159X](//www.worldcat.org/issn/1570-159X).
20. [â†‘](#cite_ref-20) Eipe, N., Penning, J. (2011). ["Postoperative respiratory depression associated with pregabalin: A case series and a preoperative decision algorithm"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206785/). *Pain Research & Management : The Journal of the Canadian Pain Society*. **16** (5): 353â€“356. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1203-6765](//www.worldcat.org/issn/1203-6765).
21. [â†‘](#cite_ref-21) [*Pregabalin*](https://www.epilepsy.com/tools-resources/seizure-medication-list/pregabalin)
22. [â†‘](#cite_ref-22) Ryvlin, P., Perucca, E., Rheims, S. (December 2008). ["Pregabalin for the management of partial epilepsy"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646650/). *Neuropsychiatric Disease and Treatment*. **4** (6): 1211â€“1224. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1176-6328](//www.worldcat.org/issn/1176-6328).
23. [â†‘](#cite_ref-23) *Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence*. Canadian Agency for Drugs and Technologies in Health. 2012.
24. [â†‘](#cite_ref-24) Olaizola, I., Ellger, T., Young, P., BÃ¶sebeck, F., Evers, S., Kellinghaus, C. (1 April 2006). ["Pregabalin-associated acute psychosis and epileptiform EEG-changes"](https://www.sciencedirect.com/science/article/pii/S105913110600029X). *Seizure*. **15** (3): 208â€“210. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.seizure.2006.02.004](//doi.org/10.1016%2Fj.seizure.2006.02.004). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1059-1311](//www.worldcat.org/issn/1059-1311).
25. [â†‘](#cite_ref-25) Mousailidis, G., Papanna, B., Salmon, A., Sein, A., Al-Hillawi, Q. (28 February 2020). ["Pregabalin induced visual hallucinations â€“ a rare adverse reaction"](https://doi.org/10.1186/s40360-020-0395-6). *BMC Pharmacology and Toxicology*. **21** (1): 16. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1186/s40360-020-0395-6](//doi.org/10.1186%2Fs40360-020-0395-6). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [2050-6511](//www.worldcat.org/issn/2050-6511).
26. [â†‘](#cite_ref-26) Schaffer, L. C., Schaffer, C. B., Miller, A. R., Manley, J. L., Piekut, J. A., Nordahl, T. E. (May 2013). "An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder". *Journal of Affective Disorders*. **147** (1â€“3): 407â€“410. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.jad.2012.09.005](//doi.org/10.1016%2Fj.jad.2012.09.005). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1573-2517](//www.worldcat.org/issn/1573-2517).
27. [â†‘](#cite_ref-27) Yukawa, T., Suzuki, Y., Fukui, N., Otake, M., Sugai, T., Someya, T. (February 2013). ["Manic symptoms associated with pregabalin in a patient with conversion disorder"](https://onlinelibrary.wiley.com/doi/10.1111/pcn.12012). *Psychiatry and Clinical Neurosciences*. **67** (2): 129â€“130. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/pcn.12012](//doi.org/10.1111%2Fpcn.12012). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1323-1316](//www.worldcat.org/issn/1323-1316).
28. [â†‘](#cite_ref-28) Becker, H. C., Myrick, H., Veatch, L. M. (1 July 2006). ["PREGABALIN IS EFFECTIVE AGAINST BEHAVIORAL AND ELECTROGRAPHIC SEIZURES DURING ALCOHOL WITHDRAWAL"](http://academic.oup.com/alcalc/article/41/4/399/162460/PREGABALIN-IS-EFFECTIVE-AGAINST-BEHAVIORAL-AND). *Alcohol and Alcoholism*. **41** (4): 399â€“406. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/alcalc/agl029](//doi.org/10.1093%2Falcalc%2Fagl029). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1464-3502](//www.worldcat.org/issn/1464-3502).
29. [â†‘](#cite_ref-29) KÃ¤mmerer, N., Lemenager, T., Grosshans, M., Kiefer, F., Hermann, D. (11 June 2012). ["Pregabalin zur Reduktion von Opiatentzugssymptomen"](http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1305042). *Psychiatrische Praxis*. **39** (07): 351â€“352. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1055/s-0032-1305042](//doi.org/10.1055%2Fs-0032-1305042). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0303-4259](//www.worldcat.org/issn/0303-4259).
30. [â†‘](#cite_ref-30) Herman, A. I., Waters, A. J., McKee, S. A., Sofuoglu, M. (April 2012). ["Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers"](http://link.springer.com/10.1007/s00213-011-2507-x). *Psychopharmacology*. **220** (3): 611â€“617. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s00213-011-2507-x](//doi.org/10.1007%2Fs00213-011-2507-x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0033-3158](//www.worldcat.org/issn/0033-3158).
31. [â†‘](#cite_ref-31) Guglielmo, R., Martinotti, G., Clerici, M., Janiri, L. (November 2012). ["Pregabalin for Alcohol Dependence: A Critical Review of the Literature"](http://link.springer.com/10.1007/s12325-012-0061-5). *Advances in Therapy*. **29** (11): 947â€“957. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s12325-012-0061-5](//doi.org/10.1007%2Fs12325-012-0061-5). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0741-238X](//www.worldcat.org/issn/0741-238X).
32. [â†‘](#cite_ref-32) Oulis, P., Konstantakopoulos, G., Kouzoupis, A. V., Masdrakis, V. G., Karakatsanis, N. A., Karapoulios, E., Kontoangelos, K. A., Papadimitriou, G. N. (June 2008). ["Pregabalin in the discontinuation of long-term benzodiazepines' use"](https://onlinelibrary.wiley.com/doi/10.1002/hup.937). *Human Psychopharmacology: Clinical and Experimental*. **23** (4): 337â€“340. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/hup.937](//doi.org/10.1002%2Fhup.937). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0885-6222](//www.worldcat.org/issn/0885-6222).
33. [â†‘](#cite_ref-33) <https://doi.org/10.1101/cshperspect.a022863>
34. [â†‘](#cite_ref-34) <https://doi.org/10.1111/j.0013-9580.2004.455003.x>
35. [â†‘](#cite_ref-35) <https://doi.org/10.1111/j.0013-9580.2004.455003.x>
36. [â†‘](#cite_ref-36) Lyrica material data sheet | <http://web.archive.org/web/20161203214718/http://www.pfizer.com/files/products/material_safety_data/722.pdf>
37. [â†‘](#cite_ref-37) Wood, D. M., Berry, D. J., Glover, G., Eastwood, J., Dargan, P. I. (December 2010). ["Significant Pregabalin Toxicity Managed with Supportive Care Alone"](http://link.springer.com/10.1007/s13181-010-0052-3). *Journal of Medical Toxicology*. **6** (4): 435â€“437. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s13181-010-0052-3](//doi.org/10.1007%2Fs13181-010-0052-3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1556-9039](//www.worldcat.org/issn/1556-9039).
38. [â†‘](#cite_ref-38) [*Lyrica (pregabalin) for Fibromyalgia: Uses, Dosage, Side Effects, Interactions, Warnings*](https://www.rxlist.com/lyrica-drug.htm)
39. [â†‘](#cite_ref-39) Lyrica package insert | <http://labeling.pfizer.com/ShowLabeling.aspx?id=561#section-10>
40. [â†‘](#cite_ref-40) [*Ja, pregabalin kan misbrukes! - Tidsskrift for Den norske legeforening*](http://web.archive.org/web/20160407131805/http://tidsskriftet.no/article/2029812), 2016
41. [â†‘](#cite_ref-41) "Gabapentin and pregabalin: abuse and addiction". *Prescrire International*. **21** (128): 152â€“154. June 2012. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1167-7422](//www.worldcat.org/issn/1167-7422).
42. [â†‘](#cite_ref-42) Song, H.-K. (October 2013). "Serotonin syndrome with perioperative oxycodone and pregabalin". *Pain Physician*. **16** (5): E632â€“633. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [2150-1149](//www.worldcat.org/issn/2150-1149).
43. [â†‘](#cite_ref-43) Kavoussi, R. (July 2006). ["Pregabalin: From molecule to medicine"](https://linkinghub.elsevier.com/retrieve/pii/S0924977X06000733). *European Neuropsychopharmacology*. **16**: S128â€“S133. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.euroneuro.2006.04.005](//doi.org/10.1016%2Fj.euroneuro.2006.04.005). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0924-977X](//www.worldcat.org/issn/0924-977X).
44. [â†‘](#cite_ref-44) Marks, D. M., Patkar, A. A., Masand, P. S., Pae, C.-U. (June 2009). ["Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796047/). *Psychiatry Investigation*. **6** (2): 55â€“58. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.4306/pi.2009.6.2.55](//doi.org/10.4306%2Fpi.2009.6.2.55). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1738-3684](//www.worldcat.org/issn/1738-3684).
45. [â†‘](#cite_ref-45) [*AMVV - Verordnung Ã¼ber die Verschreibungspflicht von Arzneimitteln*](https://www.gesetze-im-internet.de/amvv/BJNR363210005.html)
46. [â†‘](#cite_ref-46) <https://nhi.no/for-helsepersonell/nytt-om-legemidler/pregabalin-lyrica-flyttes-til-reseptgruppe-b/>
47. [â†‘](#cite_ref-47) <https://lakemedelsverket.se/Alla-nyheter/NYHETER---2018/Pregabalin-narkotikaklassas/>
48. [â†‘](#cite_ref-48) YEÅÄ°L REÃ‡ETEYE TABÄ° Ä°LAÃ‡LAR | <https://www.titck.gov.tr/storage/Archive/2019/contentFile/01.04.2019%20SKRS%20Ye%C5%9Fil%20Re%C3%A7eteli%20%C4%B0la%C3%A7lar%20Aktif%20SON%20-%20G%C3%9CNCEL_58b1ff4a-2e1c-4867-bad7-eec855d6162a.pdf>
49. [â†‘](#cite_ref-49) [*The Misuse of Drugs Act 1971 (Amendment) Order 2018*](https://www.legislation.gov.uk/uksi/2018/1356/article/2/made)
50. [â†‘](#cite_ref-50) [*Title 21 CFR - PART 1308 - Section 1308.15 Schedule V*](http://web.archive.org/web/20161017105621/https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_15.htm), 2016